Drug Trial Radar · NCT06465108
Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism
Last checked: Nov 20, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Aug 8, 2024
Primary completion
May 23, 2025
Study completion Jun 4, 2025
Sponsor
- Lead sponsor
- MBX BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- Jun 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the safety and tolerability of MBX 2109 administered once weekly to patients with hypoparathyroidism.
Conditions
- Hypoparathyroidism
Interventions
MBX 2109Drug
Supplied as 1.5 mg per vial reconstituted in 1.4 mL water for injection to a concentration of 1.0 mg/mL
PlaceboOther
Supplied in 1.4 mL water for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the effect of pooled weekly doses of MBX 2109 on the proportion of responder patients defined by serum calcium levels and treatment with active vitamin D and calcium supplements at Week 12/Visit 15Time frame: Week 12
Locations
33 sites in 3 countries. Site status is shown where the registry gives one.
MBX Biosciences Investigational Site
Sacramento, California
MBX Biosciences Investigational Site
Jacksonville, Florida
MBX Biosciences Investigational Site
Jacksonville, Florida
MBX Biosciences Investigational Site
Miami, Florida
MBX Biosciences Investigational Site
Macon, Georgia
MBX Biosciences Investigational Site
Chicago, Illinois
MBX Biosciences Investigational Site
Chicago, Illinois
MBX Biosciences Investigational Site
Jackson, Mississippi
MBX Biosciences Investigational Site
St Louis, Missouri
MBX Biosciences Investigational Site
Omaha, Nebraska
MBX Biosciences Investigational Site
Las Vegas, Nevada
MBX Biosciences Investigational Site
Reno, Nevada
MBX Biosciences Investigational Site
Albany, New York
MBX Biosciences Investigational Site
Great Neck, New York
MBX Biosciences Investigational Site
New York, New York
MBX Biosciences Investigational Site
The Bronx, New York
MBX Biosciences Investigational Site
Greenville, North Carolina
MBX Biosciences Investigational Site
Cleveland, Ohio
MBX Biosciences Investigational Site
Columbus, Ohio
MBX Biosciences Investigational Site
Philadelphia, Pennsylvania
MBX Biosciences Investigational Site
Dallas, Texas
MBX Biosciences Investigational Site
El Paso, Texas
MBX Biosciences Investigational Site
Fort Worth, Texas
MBX Biosciences Investigational Site
Round Rock, Texas
MBX Biosciences Investigational Site
San Antonio, Texas
MBX Biosciences Investigational Site
Weslaco, Texas
MBX Biosciences Investigational Site
Madison, Wisconsin
MBX Biosciences Investigational Site
Córdoba, Argentina
MBX Biosciences Investigational Site
San Miguel de Tucumán, Argentina
MBX Biosciences Investigational Site
CABA, Buenos Aires, Argentina
MBX Biosciences Investigational Site
CABA, Buenos Aires, Argentina
MBX Biosciences Investigational Site
Río Cuarto, Córdoba Province, Argentina
MBX Biosciences Investigational Site
Samsun, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.